annb0t
Top 20
LONDON, UK / ACCESSWIRE / November 2, 2022 / Kazia Therapeutics' Q123 cash flow report provided an update on the company's financial position and business progress. While the quarter was dominated by lead asset paxalisib hitting a roadblock (failing to graduate to stage two of the GBM AGILE study), the period was also marked by clinical progress across other serious indications such as pediatric brain cancers and brain metastases. With multiple studies expected to read-out in CY23, the next few ...
>>> Read more: Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates
>>> Read more: Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates
